Surgery | Radiotherapy | Octreotide, lanreotide | Cabergoline | Pegvisomant | ||
Microadenoma | Macroadenoma | |||||
Normal IGF-1 | 80-90% | 40% | 50% at 10 years | 50% | 40% | 95% |
Adenoma shrinkage | 95% | 70% | 95% | 50% | No data | Not expected |
Advantages | Potential cure reduction | Rapid size reduction | Oral administration | |||
Disadvantages | Recurrence: 5-10% | Regrowth of adenoma | Slow | Injection | Injection | |
Complications | ||||||
Hypopituitarism | Rare | 15% | 50% at 10 years | None | None | None |
Other | Diabetes insipidus, 5% | Diabetes insipidus, 10% | Neurological deficits | GI symptoms, gallstones | Nausea, lassitude | Elevated liver enzymes |
Do you want to add Medilib to your home screen?